[Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs 
in Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) frequently harbors epidermal growth factor receptor (EGFR) mutations.
• Acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) like gefitinib is a major cause of disease progression in NSCLC patients.
• The molecular mechanisms underlying EGFR-TKI resistance are complex and not fully elucidated.

Purpose of the Study:

• To review the current understanding of long non-coding RNAs (lncRNAs).
• To summarize the emerging role of lncRNAs in mediating resistance to EGFR-TKIs in NSCLC.
• To highlight knowledge gaps in lncRNA-mediated EGFR-TKI resistance.

Main Methods:

• Literature review
• Synthesis of current research findings
• Analysis of molecular mechanisms

Main Results:

• Long non-coding RNAs (lncRNAs) are increasingly recognized as key players in cancer development and progression.
• Evidence suggests that specific lncRNAs can influence EGFR-TKI sensitivity and resistance through various molecular pathways.
• Dysregulation of lncRNAs contributes to the complex mechanisms of acquired resistance.

Conclusions:

• lncRNAs represent a significant, yet understudied, factor in EGFR-TKI resistance in NSCLC.
• Further research into lncRNA function is crucial for understanding and overcoming treatment resistance.
• Targeting lncRNAs may offer novel therapeutic strategies for overcoming EGFR-TKI resistance in NSCLC.